Birth Outcomes for Pregnant Women with HIV Using Tenofovir-Emtricitabine.
N Engl J Med. 2018.
PMID: 29694825
Free PMC article.
Search Page
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 2010 | 1 |
| 2011 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
Search Results
9 results
Results by year
Citations
1
article
found by citation matching
Search results
Page 1
Birth Outcomes for Pregnant Women with HIV Using Tenofovir-Emtricitabine.
N Engl J Med. 2018 Apr 26;378(17):1593-1603. doi: 10.1056/NEJMoa1701666.
N Engl J Med. 2018.
PMID: 29694825
Free PMC article.
BACKGROUND: In a previous trial of antiretroviral therapy (ART) involving pregnant women with human immunodeficiency virus (HIV) infection, those randomly assigned to receive tenofovir, emtricitabine, and ritonavir-boosted lopinavir (TDF-FTC-LPV …
BACKGROUND: In a previous trial of antiretroviral therapy (ART) involving pregnant women with human immunodeficiency virus ( …
Pregnancy outcomes in women living with HIV and HIV-negative women in South Africa: Cohort analysis based on bias-corrected gestational age.
Paediatr Perinat Epidemiol. 2022 Jul;36(4):525-535. doi: 10.1111/ppe.12837. Epub 2021 Dec 10.
Paediatr Perinat Epidemiol. 2022.
PMID: 34890057
METHODS: Pregnant women, HIV-negative or living with HIV (WLHIV), were enrolled at first antenatal care visit and followed through delivery. ...RESULTS: Of 3952 women enrolled, 37% were WLHIV (mostly using tenofovir + emtricitabine …
METHODS: Pregnant women, HIV-negative or living with HIV (WLHIV), were enrolled at first antenatal care visit an …
Safety surveillance for PrEP in pregnant and breastfeeding women.
Front Reprod Health. 2023 Sep 29;5:1221101. doi: 10.3389/frph.2023.1221101. eCollection 2023.
Front Reprod Health. 2023.
PMID: 37854936
Free PMC article.
Review.
Pre-exposure prophylaxis (PrEP) reduces the risk of HIV acquisition. Currently available products include oral tenofovir/emtricitabine (TDF/FTC) and tenofovir alafenamide (TAF)/FTC), long-acting cabotegravir (CAB-LA) and the dapivirine ring (DVR). All …
Pre-exposure prophylaxis (PrEP) reduces the risk of HIV acquisition. Currently available products include oral tenofovir/em …
Does HIV infection modify the relationship between pre-pregnancy body mass index and adverse birth outcomes?
Paediatr Perinat Epidemiol. 2020 Nov;34(6):713-723. doi: 10.1111/ppe.12688. Epub 2020 Jun 3.
Paediatr Perinat Epidemiol. 2020.
PMID: 32490582
HIV-infected women initiated ART (tenofovir-emtricitabine/lamivudine-efavirenz) in pregnancy. ...We used modified Poisson regression to estimate risk ratios (RR) for associations between pre-pregnancy BMI and adverse birth outcomes and ex …
HIV-infected women initiated ART (tenofovir-emtricitabine/lamivudine-efavirenz) in pregnancy. ...We used modifie …
Antiretroviral therapy use during pregnancy and adverse birth outcomes in South African women.
Int J Epidemiol. 2017 Oct 1;46(5):1678-1689. doi: 10.1093/ije/dyx136.
Int J Epidemiol. 2017.
PMID: 29040569
Free PMC article.
In analysis we compared birth outcomes between HIV-infected and -uninfected women, and HIV-infected women who initiated ART before vs during pregnancy. RESULTS: In 1554 women (mean age 29 years) with live singleton births at …
In analysis we compared birth outcomes between HIV-infected and -uninfected women, and HIV-infected wo …
Association between HIV antiretroviral therapy and preterm birth based on antenatal ultrasound gestational age determination: a comparative analysis.
AIDS. 2019 Dec 1;33(15):2403-2413. doi: 10.1097/QAD.0000000000002367.
AIDS. 2019.
PMID: 31764105
Free PMC article.
Clinical Trial.
OBJECTIVE: To evaluate the association between HIV antiretroviral therapy (ART) and preterm birth (PTB), when defined by gold standard antenatal ultrasound versus newborn exam. ...We fit multivariable logistic regression models, adjusting for maternal characteristic …
OBJECTIVE: To evaluate the association between HIV antiretroviral therapy (ART) and preterm birth (PTB), when defined by gold …
Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates.
Antimicrob Agents Chemother. 2011 Jan;55(1):331-7. doi: 10.1128/AAC.00631-10. Epub 2010 Oct 18.
Antimicrob Agents Chemother. 2011.
PMID: 20956588
Free PMC article.
Clinical Trial.
The aim of the present study was to describe the nevirapine (NVP) pharmacokinetics (PK) in pregnant women and their neonates and to evaluate the transplacental drug transfer and administration scheme for the prevention of mother-to-child transmission. Thirty-eight …
The aim of the present study was to describe the nevirapine (NVP) pharmacokinetics (PK) in pregnant women and their neonates a …
Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention.
N Engl J Med. 2016 Nov 3;375(18):1726-1737. doi: 10.1056/NEJMoa1511691.
N Engl J Med. 2016.
PMID: 27806243
Free PMC article.
Clinical Trial.
BACKGROUND: Randomized-trial data on the risks and benefits of antiretroviral therapy (ART) as compared with zidovudine and single-dose nevirapine to prevent transmission of the human immunodeficiency virus (HIV) in HIV-infected pregnant women with hig …
BACKGROUND: Randomized-trial data on the risks and benefits of antiretroviral therapy (ART) as compared with zidovudine and single-dose nevi …
Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study.
Lancet Glob Health. 2018 Jul;6(7):e804-e810. doi: 10.1016/S2214-109X(18)30218-3. Epub 2018 Jun 4.
Lancet Glob Health. 2018.
PMID: 29880310
Free PMC article.
In 2016, Botswana changed first-line ART from efavirenz-tenofovir-emtricitabine to dolutegravir-tenofovir-emtricitabine, including for pregnant women. ...INTERPRETATION: Adverse birth outcomes were similar among pregnant …
In 2016, Botswana changed first-line ART from efavirenz-tenofovir-emtricitabine to dolutegravir-tenofovir-emtricitab …
Cite